CardioBIVA
Bioelectrical impedance vector analysis medical device as a novel Internet of Things telemedicine system for monitoring congestive heart failure patients from home
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CardioBIVA project word cloud
Explore the words cloud of the CardioBIVA project. It provides you a very rough idea of what is the project "CardioBIVA" about.
Project "CardioBIVA" data sheet
The following table provides information about the project.
| Coordinator |
IRIDEON SL
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.irideon.eu |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-1-2014 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-06-01 to 2015-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | IRIDEON SL | ES (BARCELONA) | coordinator | 50˙000.00 |
Map
Project objective
IRIDEON is a Spanish-German SME, which develops and provides Internet of Things (IoT) sensor solutions based on a proprietary framework. We have partnered with HERIM, a distributor leader in the diagnostics market for lifestyle, body composition and vascular monitoring. We have been working in the development of a disruptive way to improve the monitoring of congestive heart failure (CHF) patients from home. We aim to prototype, test and commercialise an IoT telemedicine system based on bioelectrical impedance vector analysis (BIVA): CardioBIVA. One in five people in Europe will experience heart failure. CHF is the most common cause of hospitalization in people aged over 65, and half of these die 5 years after the first hospitalization. Heart problems cause 29% of total global deaths, and in Europe 47% of all deaths- over 4 million/year. CHF costs the EU economy €60 billion a year. We have a clear business opportunity, as an IoT telemedicine system that would enable an easy and frequent monitoring of a reliable physiological indicator to CHF in the home environment is expected to substantially reduce hospitalizations and, as a result, lower medical costs and impact on life. The telemedicine industry has become an integral part of the European economy, investing approximately €200 billion a year. The shipments of telemedicine “gateways” for CHF are expected to reach 561,000 in 2015 and over 3.5 million units by 2020. We already have the primary distribution covered by HERIM’s consolidated sales network in Iberoamerican countries, complemented by IRIDEON’s e-commerce channel. The secondary channel will be other Medical Equipment and Supply companies and Insurance companies. With the exploitation of CardioBIVA we expect to create 35 new job positions, internationalize and enter new markets where telemedicine programmes are limited by resources, and increased revenue from sales generated by CardioBIVA (NPV=€8.9 million, ROI=0.70).
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOBIVA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CARDIOBIVA" are provided by the European Opendata Portal: CORDIS opendata.